Drug Trial Radar · NCT01566552
Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis
Last checked: Nov 20, 2026Latest source record: Jan 22, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,300
Planned (sponsor's estimate)
Start
Jun 2014
Primary completion
Dec 2016
Study completion Dec 2017
Sponsor
- Lead sponsor
- Banaras Hindu UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Rajendra Memorial Research Institute of Medical Sciences
- First posted
- Mar 29, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to determine the use of delivering point of care, rapid diagnosis with rK39 and treatment with AmBisome single dose of 10 mg/kg when administrated in the Primary Health Center (PHC) settings with regard to operational feasibility, safety and final cure rate at 6 months after end of treatment. Point of care diagnosis and treatment (PCDT) at the PHC level would bring the best available interventions closer to the patients with visceral leishmaniasis (VL) whose villages are within several kilometers of the PHC. This would support the VL elimination program in the Indian subcontinent.
Conditions
- Visceral Leishmaniasis
Interventions
AMBISOMEDrug
SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
Primary outcomes
What the sponsor says the trial is designed to measure.
- CLINICAL CURETime frame: 24 MONTHS
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kala Azar Medical Research Center
Muzaffarpur, Bihar, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.